Key result
Clevidipine infusion maintains target SBP ~91% of the time in acute ICH.
Why the study?
Higher blood pressure variability within the first 24 hours of acute intracerebral hemorrhage may be associated with poorer outcomes, and the impact of commonly utilized intravenous antihypertensives on blood pressure variability is not well characterized. Clevidipine's rapid onset and short half-life may be ideal to promptly achieve goal systolic blood pressure with minimal variability.
Does intravenous clevidipine limit blood pressure variability and rapidly achieve goal systolic blood pressure in adult patients with acute spontaneous intracerebral hemorrhage?
Does intravenous clevidipine limit blood pressure variability and rapidly achieve goal systolic blood pressure in adult patients with acute spontaneous intracerebral hemorrhage?
Preliminary data from 4 patients suggest intravenous clevidipine rapidly achieves target SBP (130-160 mmHg) within a median of 6 minutes and maintains tight blood pressure control with minimal variability in acute intracerebral hemorrhage.
Answers are grounded in this paper and cite their sources.
Clevidipine may lower early BPV in acute ICH; leaves open outcome benefit versus alternatives in randomized trials.
Introduction: Timely blood pressure control is an essential part of intracerebral hemorrhage (ICH) management. Blood pressure variability (BPV) depicts blood pressure over time and higher BPV within the first 24 hours may be associated with poorer outcomes. Intravenous antihypertensives are commonly utilized to control blood pressure in acute ICH however their impact on BPV is not well characterized. Clevidipine’s rapid onset and short half-life may be ideal to promptly achieve a goal systolic blood pressure (SBP) with minimal BPV. The goal of this study is to prospectively evaluate the impact of clevidipine on BPV. Methods: This single-center, single-arm, open-label, prospective study is evaluating 20 patients between January 2022 to 2024. Adult patients with confirmed acute spontaneous ICH are eligible if baseline SBP is > 160 mm Hg prior to clevidipine initiation. Clevidipine is titrated to a goal SBP of 130-160 mmHg. Beat to beat values of SBP derived from arterial line are captured using ICM+®. BPV is reported as standard deviation and coefficient of variation of the SBP calculated every minute for the duration of therapy. Secondary endpoints include time to SBP goal, percent time within goal and safety parameters. Relative and absolute hypotension are defined as SBP < 130 mmHg and < 90 mmHg, respectively. Data reported in mean ± SD or median (IQR). Results: Preliminary data for the first four patients is reported. All patients were African American with an age of 70 ± 14 years. Patients presented with a baseline Glasgow Coma Scale of 12 (8-15), National Institutes of Health Stroke Scale of 13 (5-26) and ICH Score of 2 (1-3). Baseline SBP was 172 ± 7 mmHg. SBP during clevidipine infusion was 147.5 ± 3.68 mm Hg and a coefficient variant of 0.025. Time to SBP goal was 6 (6-8.25) minutes and maximum dose of clevidipine was 10 (8-18) mg/hr. Patients remained within the SBP goal for 91.1% of time on therapy, with a therapy duration of 11.2 ± 1 hours. Relative hypotension occurred 2.3% of time on therapy. No episodes of absolute hypotension were reported. Conclusions: Preliminary results suggest that clevidipine has limited BPV and achieves goal SBP rapidly and safely. Additionally, patients remain at goal during the duration of the infusion.
No takes yet. Share an insight, caveat, or question.
Conroy et al. (2022) studied Acute spontaneous intracerebral hemorrhage with baseline SBP > 160 mm Hg (n=4). Clevidipine was evaluated on Blood pressure variability (standard deviation and coefficient of variation of SBP calculated every minute for the duration of therapy). Clevidipine infusion in acute ICH achieved a mean SBP of 147.5 ± 3.68 mmHg with a coefficient of variation of 0.025 and 91.1% time within goal.
Synapse has enriched 10 related papers. Consider them for comparative context: